Porton Pharma Solutions Ltd (Porton) is a contract development and manufacturing organization that provides small-molecule active pharmaceutical ingredients, dosage forms and biologics manufacturing services. The company offers API process development, manufacturing, technology platform, quality studies and analytical research and development and CMC registration support services. Porton also provides drug product CDMO services, biologics CDMO services and client-oriented program management services, among others. It operates research and development centers in China, manufacturing facilities in China and process technology centers in the US . Porton is headquartered in Chongqing, China.
Porton Pharma Solutions Ltd premium industry data and analytics
Products and Services
Products | Services |
---|---|
Active Pharmaceutical Ingredients | Gene and Cell Therapy Services |
Small Molecule API and Intermediates CDMO Services | |
API-Preparation Integrated CDMO Solution | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Plans/Strategy | In August, the company announced its plans to acquire 30% stake in Hubei Yuyang Pharmaceutical Co., Ltd. |
2022 | Plans/Strategy | In August, the company announced its plans to invest into a new state of the Art cGMP/API facility. |
2022 | Contracts/Agreements | In August, the company announced a strategic cooperation with Suzhou Royaltech Med Co., Ltd. to further integrate the resources and capabilities. |
Competitor Comparison
Key Parameters | Porton Pharma Solutions Ltd | Zhejiang Huahai Pharmaceutical Co Ltd | Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | Shandong Xinhua Pharmaceutical Co Ltd | Viva Biotech Holdings |
---|---|---|---|---|---|
Headquarters | China | China | China | China | China |
City | Chongqing | Taizhou | Tianjin | Zibo | Shanghai |
State/Province | Chongqing | Zhejiang | Tianjin | Shandong | Shanghai |
No. of Employees | 5,377 | 7,682 | 4,913 | 6,839 | 2,271 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Ju Nianfeng | General Manager; Chairman | Executive Board | 2018 | 51 |
Chen Hui | Deputy General Manager; Chief Financial Officer | Senior Management | 2022 | 44 |
Ji Yaohui | Senior Deputy General Manager | Senior Management | 2022 | 44 |
Zhu Po | Deputy General Manager | Senior Management | 2022 | 53 |
Wang Rui | Deputy General Manager | Senior Management | 2022 | 57 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer